HI

Health Innovation Fund

North America, California, United States, Oakland

Description

Health Innovation Fund is a London-based venture capital fund that invests in innovative healthcare-related projects.

Investor Profile

Health Innovation Fund has made 8 investments, with 0 in the past 12 months and 38% as lead.

Stage Focus

  • Seed (38%)
  • Series Unknown (25%)
  • Series B (25%)
  • Series A (13%)

Country Focus

  • The Netherlands (75%)
  • United States (25%)

Industry Focus

  • Health Care
  • Medical
  • Biotechnology
  • Medical Device
  • Primary And Urgent Care
  • Artificial Intelligence (Ai)
  • Health Diagnostics
  • Hospital
  • Neuroscience
  • Insurance
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Health Innovation Fund frequently co-invest with?

Thuja Capital
Europe, Utrecht, The Netherlands, Utrecht
Co-Investments: 3
OostNL
Europe, Gelderland, The Netherlands, Apeldoorn
Co-Investments: 1
NV Industriebank LIOF
Europe, Limburg, The Netherlands, Maastricht
Co-Investments: 1
M
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1
Limburg Ventures
Europe, Limburg, The Netherlands, Maastricht
Co-Investments: 2
Inkef
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1
Gilde Healthcare
Europe, Utrecht, The Netherlands, Utrecht
Co-Investments: 1
Holland Capital
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 2
Elevate Capital
North America, Oregon, United States, Hillsboro
Co-Investments: 1
Van Herk Ventures
Europe, Zuid-Holland, The Netherlands, Rotterdam
Co-Investments: 1

Which angels does Health Innovation Fund often collaborate with?

AI
North America, California, United States, Los Angeles
Shared Deals: 1

What are some of recent deals done by Health Innovation Fund?

Obatala Sciences

New Orleans, Louisiana, United States

Obatala Sciences is an assay and research tool development tissue-chip company that specializes in fat-chips.

BiotechnologyHealth CareLife Science
SeedJan 22, 2021
Amount Raised: $1,100,000
Prolira makers of DeltaScan®

Utrecht, Utrecht, The Netherlands

DeltaScan® Brain State Monitor is an EEG bedside device with a validated algorithm to support clinicians to optimize patient recovery.

Artificial Intelligence (AI)Health CareHealth DiagnosticsHospitalMedicalMedical DeviceNeuroscience
SeedNov 1, 2018
Amount Raised: $2,052,449
FABPulous

Maastricht, Limburg, The Netherlands

FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.

BiotechnologyHealth CareMedicalPrimary and Urgent Care
Series UnknownOct 17, 2017
Prolira makers of DeltaScan®

Utrecht, Utrecht, The Netherlands

DeltaScan® Brain State Monitor is an EEG bedside device with a validated algorithm to support clinicians to optimize patient recovery.

Artificial Intelligence (AI)Health CareHealth DiagnosticsHospitalMedicalMedical DeviceNeuroscience
Series UnknownSep 27, 2016
Amount Raised: $1,234,014
Nightbalance

Delft, Zuid-Holland, The Netherlands

Nightbalance has created a device called the Sleep Position Trainer

BiotechnologyHealth CareHome Health CareMedicalMedical Device
Series BJul 5, 2016
Amount Raised: $13,833,555
FABPulous

Maastricht, Limburg, The Netherlands

FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.

BiotechnologyHealth CareMedicalPrimary and Urgent Care
Series BFeb 4, 2015
Amount Raised: $2,040,000
DirectDerm

East Palo Alto, California, United States

DirectDerm provides teledermatology consultative services for patients facing skin-related medical problems.

Health CareInsuranceMedical
SeedDec 6, 2011
Amount Raised: $240,000
FABPulous

Maastricht, Limburg, The Netherlands

FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.

BiotechnologyHealth CareMedicalPrimary and Urgent Care
Series AJan 11, 2010